Neumora Therapeutics, Inc.

Neumora Therapeutics, Inc. (NMRA) priced its initial public offering on Sep 18, 2023 at $17.00 per share, within its $16.00–$18.00 range, raising $250.1M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $2.58B. Latham & Watkins advised the company and Cooley advised the underwriters.

Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for brain diseases. Its pipeline has seven clinical and preclinical neuroscience programs targeting novel mechanisms for neuropsychiatric disorders and neurodegenerative diseases.

Status

IPO

Ticker

NMRA

Exchange

Nasdaq Global Select

Priced

Sep 18, 2023

IPO price

$17.00

Price range

$16.00–$18.00

Raised

$250.1M

Market cap at IPO price

$2.58B

First filed

Aug 25, 2023

Company counsel

Latham & Watkins

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.